Based on the most recent data from Aug 21, 2026, NBIX's PEG ratio comes in at 0.21. This metric factors in a PE of 21.64 with an earnings growth rate of 102.6%. Relative to the 0.97 average from the previous four quarters, the PEG ratio has plunged by 78%.
Looking at the last eight years, NBIX's PEG ratio has has been around 2.3 on average. At 0.21, today's PE to growth ratio sits 91% below its historical average. Within the last eight years, the Jun 2025 quarter recorded the highest PEG value at 24.08. At 0.02, the Dec 2020 quarter showed the minimum PEG ratio in this period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.71 | 29.49 | 41.5% |
| 2024 | 1.22 | 40.15 | 32.8% |
| 2023 | 0.87 | 51.47 | 59% |
| 2022 | 1.07 | 74.19 | 69.5% |
| 2021 | N/A | 89.65 | -78.3% |
| 2020 | 0.02 | 21.88 | 995% |
| 2019 | 3.64 | 268.73 | 73.9% |
| 2018 | 2.72 | 310.48 | 114.2% |
| 2017 | N/A | N/A | 0.6% |
| 2016 | N/A | N/A | -55.2% |
| 2015 | N/A | N/A | -29.6% |
| 2014 | N/A | N/A | -17.4% |
| 2013 | N/A | N/A | -962.5% |
| 2012 | N/A | 93.5 | -88.2% |
| 2011 | 0.02 | 12.5 | 553.3% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.23 | 23.91 | 102.6% |
| Mar 2026 | 0.16 | 19.63 | 121.5% |
| Dec 2025 | 0.71 | 29.49 | 41.5% |
| Sep 2025 | 2.78 | 32.57 | 11.7% |
| Jun 2025 | 24.08 | 36.12 | 1.5% |
| Mar 2025 | N/A | 36.5 | -19.6% |
| Dec 2024 | 1.22 | 40.15 | 32.8% |
| Sep 2024 | 0.31 | 29.85 | 96.9% |
| Jun 2024 | 0.46 | 40.14 | 87.4% |
| Mar 2024 | 0.08 | 36.58 | 462.7% |
| Dec 2023 | 0.87 | 51.47 | 59% |
| Sep 2023 | 0.26 | 57.4 | 221.3% |
| Jun 2023 | 0.04 | 51.53 | 1,307.7% |
| Mar 2023 | N/A | 151.07 | -11.8% |
| Dec 2022 | 1.07 | 74.19 | 69.5% |
Measured against past performance, NBIX's PEG ratio is below the 3, 5 and 10-year averages.
Neurocrine Biosciences's PEG of 0.21 is below the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 0.61, Neurocrine Biosciences's PEG is 66% lower.
Compared to its peers, NBIX has a PEG ratio under stocks LLY and ABBV, while above ANIP's. With a PEG ratio of 0.21, Neurocrine Biosciences stands lower than the 0.55 peer average.
According to Aug 21, 2026 data, NBIX's PEG ratio sits at 0.21.
NBIX's 3-year PEG ratio average stands at 2.83.
NBIX's 5-year PEG ratio average stands at 2.31.
NBIX's PEG ratio peaked at 24.08 during the Jun 2025 quarter - the highest in eight years.
NBIX currently has a PEG ratio 91% below its 8-year average.
Rapid earnings growth combined with a reasonable valuation yields NBIX a PEG ratio of 0.21.
PEG equals PE divided by EPS growth (YoY TTM). As of Aug 21, 2026, Neurocrine Biosciences has a P/E ratio of 21.64. Earnings grew at 102.6% over the TTM period ending Jun 2026. Applying the formula, this produces a price to earnings growth ratio of 0.21. PEG RATIO(0.21) = PE RATIO(21.64) / EPS GROWTH(102.6%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.